Long-Term Evaluation of Allopurinol Effectiveness in the Thai Population: Insights from 10 Years of Real-World Big Data Analysis
Abstract
Objective: This study aimed to evaluate the effectiveness and safety profile of allopurinol in Songklanagarind hospital, Thailand.
Material and Methods: Electronic medical records (EMRs) of patients having undergone allopurinol treatment for gouty arthritis, or other pertinent indications, were retrospectively reviewed. The primary outcome of this study was the longitudinal measurement of uric acid levels. A linear mixed model (LMM) analysis assessed the statistical significance of uric acid reduction across hospital visits. The safety profile regarding allopurinol-related adverse drug reactions was assessed.
Results: A total of 11,277 EMRs were extracted, of which 8,801 EMRs were eligible for further analyses. These records pertain to a cohort of 3,219 unique patients whose visits were arranged chronologically from the earliest to the fifth recorded visit. Overall, uric acid level decreased after allopurinol treatment in all patients. Across subsequent visits, the analysis, using LMM, found a significant reduction in uric acid levels (χ²=1465.4, df=4, p-value<0.001), with the early reduction observed as early as the second visit. The incidence of allopurinol-related adverse reactions was 4.37% (385/8801 cases).
Conclusion: The current dosing regimen of allopurinol at Songklanagarind Hospital has demonstrated favorable treatment outcomes and continues to be effective. This data provides insights into pharmacological management and its real-world outcomes.
Keywords
Full Text:
PDFReferences
Shagroni T, Cazares AR, Kim JA, Furst DE. Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics, & drugs used in gout. In: Katzung BG, Vanderah TW, editors. Basic & Clinical Pharmacology, 15 ed. New York: McGraw-Hill; 2021.
Bardin T, Richette P. The role of febuxostat in gout. Curr Opin Rheumatol 2019;31:152-8.
FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken) 2020;72:744-60.
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 2018;378:1200-10.
Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
Yu KH, Yu CY, Fang YF. Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis. Int J Rheum Dis 2017;20:1057-71.
Dean L, Kane M. Allopurinol Therapy and HLA-B*58:01 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical Genetics Summaries. Bethesda (MD): National Center for Biotechnology Information (US); 2012.
Tassaneeyakul W, Jantararoungtong T, Chen P, Lin P-Y, Tiamkao S, Khunarkornsiri U, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009;19:704-9.
Saksit N, Tassaneeyakul W, Nakkam N, Konyoung P, Khunarkornsiri U, Chumworathayi P, et al. Risk factors of allopurinol-induced severe cutaneous adverse reactions in a Thai population. Pharmacogenet Genomics 2017;27:255-63.
Kloypan C, Koomdee N, Satapornpong P, Tempark T, Biswas M, Sukasem C. A Comprehensive review of HLA and severe cutaneous adverse drug reactions: implication for clinical pharmacogenomics and precision medicine. Pharmaceuticals (Basel) 2021;14.
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017;76:29-42.
Kutanan W, Kampuansai J, Changmai P, Flegontov P, Schröder R, Macholdt E, et al. Contrasting maternal and paternal genetic variation of hunter-gatherer groups in Thailand. Scientific Reports 2018;8:1536.
Dancause KN, Chan CW, Arunotai NH, Lum JK. Origins of the Moken Sea Gypsies inferred from mitochondrial hypervariable region and whole genome sequences. J Hum Genet 2009;54:86-93.
Deshpande D, Chhugani K, Chang Y, Karlsberg A, Loeffler C, Zhang J, et al. RNA-seq data science: from raw data to effective interpretation. Front Genet 2023;14:997383.
Hayes CJ, Cucciare MA, Martin BC, Hudson TJ, Bush K, Lo-Ciganic W, et al. Using data science to improve outcomes for persons with opioid use disorder. Subst Abus 2022;43:956-63.
Slade E, Dwoskin LP, Zhang GQ, Talbert JC, Chen J, Freeman PR, et al. Integrating data science into the translational science research spectrum: a substance use disorder case study. J Clin Transl Sci 2020;5:e29.
Goulooze SC, Zwep LB, Vogt JE, Krekels EHJ, Hankemeier T, van den Anker JN, et al. Beyond the Randomized Clinical Trial: Innovative Data Science to Close the Pediatric Evidence Gap. Clin Pharmacol Ther 2020;107:786-95.
Ehsani-Moghaddam B, Martin K, Queenan JA. Data quality in healthcare: a report of practical experience with the Canadian Primary Care Sentinel Surveillance Network data. Health Inf Manag 2021;50:88-92.
Rigobon AV, Birtwhistle R, Khan S, Barber D, Biro S, Morkem R, et al. Adult obesity prevalence in primary care users: an exploration using Canadian primary care sentinel surveillance network (CPCSSN) data. Can J Public Health 2015;106:e283-9.
Liu F, Panagiotakos D. Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Med Res Methodol 2022;22:287.
Lin WL, Liang YC, Chung KH, Chen PH, Chang YC. Using text mining and data visualization approaches for investigating mental illness from the perspective of traditional Chinese medicine. Medicina (Kaunas) 2023;59.
Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012;64:2529-36.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.